<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704535</url>
  </required_header>
  <id_info>
    <org_study_id>P04748</org_study_id>
    <nct_id>NCT00704535</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)</brief_title>
  <official_title>Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the overall safety, tolerability, and efficacy of
      Ezetimibe when used alone or in combination with a statin in patients with
      hypercholesterolemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as Measured by Number of Subjects With at Least One Adverse Event</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>Evaluation of the overall safety of ezetimibe as measured by number of subjects who experienced at least one adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Measured by Number and Type of Adverse Events.</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>Evaluation of the overall safety of ezetimibe as measured by the number and type of adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Measured by Severity of Adverse Events as Determined by the Investigator</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>To evaulate the safety of ezetimibe as measured by severity of adverse events, as determined by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator.</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>To evaluate the overall safety of ezetimibe as measured by adverse event relatedness to study drug as reported by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>To evaluate the overall safety of ezetimibe as measured by action taken by the investigator upon incidence of an adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Measured by Outcome of Adverse Events</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>To evaluate overall safety of ezetimibe as measured by outcome of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability as Measured by Subject Self-assessment</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>Evaluation of the overall tolerability of ezetimibe as measured by subject self-assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Efficacy of Ezetimibe in Lowering Serum Cholesterol Levels 28 Days After Visit 1 (Baseline)</measure>
    <time_frame>28 days after Visit 1</time_frame>
    <description>Change in mean total cholesterol values</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4105</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Subjects with hypercholesterolemia</arm_group_label>
    <description>Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>1 tablet of 10 mg once daily</description>
    <arm_group_label>Subjects with hypercholesterolemia</arm_group_label>
    <other_name>SCH 58235</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Filipino subjects with hypercholesterolemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient men or women, age 18 years and above.

          -  Patients with primary (heterozygous familial and non-familial) hypercholesterolemia or
             homozygous familial hypercholesterolemia.

        Exclusion Criteria:

          -  Known hypersensitivity to Ezetimibe.

          -  Moderate to severe hepatic insufficiency.

          -  Persistent elevation of serum transaminase levels of more than 1.5 times the upper
             limit of normal.

          -  Pregnancy or lactation.

          -  Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric
             acid (fibrates), or cyclosporine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Philippines</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <results_first_submitted>May 21, 2009</results_first_submitted>
  <results_first_submitted_qc>May 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2009</results_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
          <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3959"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed status not on Case Report Form</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
          <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age was not reported for 10 subjects</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.62" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Gender was not reported for 13 subjects</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by Number of Subjects With at Least One Adverse Event</title>
        <description>Evaluation of the overall safety of ezetimibe as measured by number of subjects who experienced at least one adverse event</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by Number of Subjects With at Least One Adverse Event</title>
          <description>Evaluation of the overall safety of ezetimibe as measured by number of subjects who experienced at least one adverse event</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Efficacy of Ezetimibe in Lowering Serum Cholesterol Levels 28 Days After Visit 1 (Baseline)</title>
        <description>Change in mean total cholesterol values</description>
        <time_frame>28 days after Visit 1</time_frame>
        <population>All enrolled subjects who had both baseline and post-treatment samples collected for cholesterol measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Efficacy of Ezetimibe in Lowering Serum Cholesterol Levels 28 Days After Visit 1 (Baseline)</title>
          <description>Change in mean total cholesterol values</description>
          <population>All enrolled subjects who had both baseline and post-treatment samples collected for cholesterol measurements</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4083"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.70" spread="47.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by Number and Type of Adverse Events.</title>
        <description>Evaluation of the overall safety of ezetimibe as measured by the number and type of adverse events.</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by Number and Type of Adverse Events.</title>
          <description>Evaluation of the overall safety of ezetimibe as measured by the number and type of adverse events.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>gastrointestinal upset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>body weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>crampy abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epigastric discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>flatulence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>leg cramps/muscle pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>oily flatus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vague abdominal discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by Severity of Adverse Events as Determined by the Investigator</title>
        <description>To evaulate the safety of ezetimibe as measured by severity of adverse events, as determined by the investigator</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by Severity of Adverse Events as Determined by the Investigator</title>
          <description>To evaulate the safety of ezetimibe as measured by severity of adverse events, as determined by the investigator</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator.</title>
        <description>To evaluate the overall safety of ezetimibe as measured by adverse event relatedness to study drug as reported by the investigator.</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator.</title>
          <description>To evaluate the overall safety of ezetimibe as measured by adverse event relatedness to study drug as reported by the investigator.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Related to treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related to treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relatedness not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event</title>
        <description>To evaluate the overall safety of ezetimibe as measured by action taken by the investigator upon incidence of an adverse event</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event</title>
          <description>To evaluate the overall safety of ezetimibe as measured by action taken by the investigator upon incidence of an adverse event</description>
          <units>adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment dosage unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment dosage reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment temporarily discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by Outcome of Adverse Events</title>
        <description>To evaluate overall safety of ezetimibe as measured by outcome of adverse events</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by Outcome of Adverse Events</title>
          <description>To evaluate overall safety of ezetimibe as measured by outcome of adverse events</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse event cleared</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event still present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event outcome not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability as Measured by Subject Self-assessment</title>
        <description>Evaluation of the overall tolerability of ezetimibe as measured by subject self-assessment</description>
        <time_frame>28 days after Visit 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
            <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability as Measured by Subject Self-assessment</title>
          <description>Evaluation of the overall tolerability of ezetimibe as measured by subject self-assessment</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe as Prescribed by the Physician in Normal Practice</title>
          <description>Filipino subjects with hypercholesterolemia who are using ezetimibe either alone or in combination with a statin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4105"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The prescribing physicians and investigators of this trial will not publish the results of any part of the study without previous written authorization from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

